Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 16/20 | 0.50 |
| ▸ | MAOA | P21397 | 3/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5164203 | 0.85 | MAOB (0.52) | MAOBMAOAADORA2BMAPTNPC1 | |
| SCHEMBL14033472 | 0.83 | MAOB (0.49) | MAOBMAOAADORA2BMAPTNPC1 | |
| SCHEMBL5160401 | 0.81 | MAOB (0.50) | MAOBMAOAADORA2BMAPTNPC1 | |
| SCHEMBL5158204 | 0.81 | MAOB (0.50) | MAOBMAOAADORA2BMAPTNPC1 | |
| SCHEMBL24170723 | 0.80 | MAOB (0.55) | MAOBMAOAADORA2BMAPTNPC1 | |
| SCHEMBL29918465 | 0.80 | MAOB (0.55) | MAOBMAOAADORA2BMAPTNPC1 | |
| SCHEMBL1919254 | 0.80 | MAPT (0.58) | MAOBMAOAADORA2BMAPTNPC1 | |
| SCHEMBL5158448 | 0.80 | MAOB (0.49) | MAOBMAOAADORA2BMAPTNPC1 | |
| SCHEMBL5158194 | 0.78 | MAOB (0.60) | MAOBMAOAADORA2BMAPTNPC1 | |
| SCHEMBL5163275 | 0.78 | MAOB (0.50) | MAOBADORA2BMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293899-B2 | Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates | LANXESS DEUTSCHLAND GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| EP-1340746-A1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | GRHPR, HPD, HAAO | MAOB 330/4885MAOA 301/4885ADORA2B 1266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.